Evaluation of clinical outcomes in patients treated with heparin or direct thrombin inhibitors during extracorporeal membrane oxygenation: a systematic review and meta-analysis

Tonna JE, Abrams D, Brodie D, Greenwood JC, Rubio Mateo-Sidron JA, Usman A, Fan E. Management of Adult Patients Supported with Venovenous Extracorporeal Membrane Oxygenation (VV ECMO): Guideline from the Extracorporeal Life Support Organization (ELSO). ASAIO J. 2021;67(6):601–10.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Le Gall A, Follin A, Cholley B, Mantz J, Aissaoui N, Pirracchio R. Veno-arterial-ECMO in the intensive care unit: From technical aspects to clinical practice. Anaesth Crit Care Pain Med. 2018;37(3):259–68.

PubMed  Article  Google Scholar 

Gattinoni L, Vassalli F, Romitti F, Vasques F, Pasticci I, Duscio E, Quintel M. Extracorporeal gas exchange: when to start and how to end? Crit Care. 2019;23(Suppl 1):203.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Chandler WL. Coagulation activation during extracorporeal membrane oxygenation (ECMO). Thromb Res. 2022;211:154–60.

CAS  PubMed  Article  Google Scholar 

Colman E, Yin EB, Laine G, Chatterjee S, Saatee S, Herlihy JP, Reyes MA, Bracey AW. Evaluation of a heparin monitoring protocol for extracorporeal membrane oxygenation and review of the literature. J Thorac Dis. 2019;11(8):3325–35.

PubMed  PubMed Central  Article  Google Scholar 

Murphy DA, Hockings LE, Andrews RK, Aubron C, Gardiner EE, Pellegrino VA, Davis AK. Extracorporeal membrane oxygenation-hemostatic complications. Transfus Med Rev. 2015;29(2):90–101.

PubMed  Article  Google Scholar 

Choi JH, Luc JGY, Weber MP, Reddy HG, Maynes EJ, Deb AK, Samuels LE, Morris RJ, Massey HT, Loforte A, et al. Heparin-induced thrombocytopenia during extracorporeal life support: incidence, management and outcomes. Ann Cardiothorac Surg. 2019;8(1):19–31.

PubMed  PubMed Central  Article  Google Scholar 

Pollak U. Heparin-induced thrombocytopenia complicating extracorporeal membrane oxygenation support: Review of the literature and alternative anticoagulants. J Thromb Haemost. 2019;17(10):1608–22.

PubMed  Article  Google Scholar 

Sheridan EA, Sekela ME, Pandya KA, Schadler A, Ather A. Comparison of Bivalirudin Versus Unfractionated Heparin for Anticoagulation in Adult Patients on Extracorporeal Membrane Oxygenation. ASAIO J. 2021;68(7):920–4.

Article  CAS  Google Scholar 

Fisser C, Winkler M, Malfertheiner MV, Philipp A, Foltan M, Lunz D, Zeman F, Maier LS, Lubnow M, Müller T. Argatroban versus heparin in patients without heparin-induced thrombocytopenia during venovenous extracorporeal membrane oxygenation: a propensity-score matched study. Crit Care. 2021;25(1):1–10.

Article  Google Scholar 

Hamzah M, Jarden AM, Ezetendu C, Stewart R. Evaluation of Bivalirudin As an Alternative to Heparin for Systemic Anticoagulation in Pediatric Extracorporeal Membrane Oxygenation. Pediatr Crit Care Med. 2020;21(9):827–34.

PubMed  Article  Google Scholar 

Liu L, Liu F, Tan J, Zhao L. Bivalirudin versus heparin in adult and pediatric patients with extracorporeal membrane oxygenation therapy: A systematic review and meta-analysis. Pharmacol Res. 2022;177:106089.

CAS  PubMed  Article  Google Scholar 

Li MJ, Shi JY, Zhang JH. Bivalirudin vs. heparin in paediatric and adult patients on extracorporeal membrane oxygenation: A meta-analysis. Br J Clin Pharmacol. 2022;88(6):2605–16.

CAS  PubMed  Article  Google Scholar 

Geli J, Capoccia M, Maybauer DM, Maybauer MO. Argatroban Anticoagulation for Adult Extracorporeal Membrane Oxygenation: A Systematic Review. J Intensive Care Med. 2022;37(4):459–71. https://doi.org/10.1177/0885066621993739.

Article  PubMed  Google Scholar 

Wells GA SB, O’Connell D, Peterson J, Welch V, Losos M, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. 2009.

Google Scholar 

Balutis KR, Bauman ME, Nelson LAR, Granoski DA, Patricia Massicotte M, Lequier LL, Ryerson LM. Prospective observational experience with bivalirudin anticoagulation in pediatric extracorporeal membrane oxygenation. ASAIO J. 2018;64:69.

Google Scholar 

Bauman M, Massicotte P, Bruce A, Granoski D, Lequier L, Ryerson L. Bivalirudin use in children on ecmo following Heparin failure. J Thromb Haemost. 2015;13:427.

Google Scholar 

Berei TJ, Lillyblad MP, Hryniewicz KM, Wilson K, Garberich R. Evaluation of systemic heparin vs. Bivalrudin anticoagulation in patients supported by extracorporeal membrane oxygenation. J Heart Lung Transplantation. 2016;35(4):S396.

Article  Google Scholar 

Berry N, Khouli C, Anderson E, Terry C, Moes M, Gutteridge D, Hage C, Wang I. Retrospective outcomes analysis of ECMO Patients Anticoagulated with Heparin vs. Bivalirudin. ASAIO J. 2017;63(5):49.

Google Scholar 

Bohman JK, Yi L, Seelhammer T. Observational case-control comparison of bivalirudin versus heparin anticoagulation for adult extracorporeal membrane oxygenation (ECMO). Am J respiratory and critical care medicine 2018;197(MeetingAbstracts).

Brown C, Scott S, Escobar M, Patel R, Holloway A, Foster C. Heparin vs. Bivalrudin for systemic anticoagulation in pediatric extracorporeal membrane oxygenation: A single center retrospective analysis. ASAIO J. 2019;65:28.

Article  CAS  Google Scholar 

Brown M, Najam F, Pocock E, Munoz P, Farrar K, Hinchey D, Lee H, Shaykhinurov E, Yamane D. Time to switch to bivalirudin for routine anticoagulation on ECMO. Critical Care Med. 2019;47(1).

Demerdash A, Snell K, Gajkowski E, Patterson J, Korzick K. 855: Ecmo bleeding complications: a single center’s experience with different anticoagulation methods. Crit Care Med. 2019;47:406–406.

Article  Google Scholar 

Gajkowski E, Demerdash A, Snell K, Patterson J, Korzick K. ECMO bleeding complications: A single center’s experience with different anticoagulation methods. ASAIO J. 2019;65:36.

Article  Google Scholar 

Giuliano K, Etchill E, Choi CW, Cho SM, Whitman G. Is bivalirudin safer than heparin for ECMO patients? Perfusion. 2020;35(1 SUPPL):221.

Google Scholar 

Hamzah M, Ezetendu C, Jarden A. A retrospective evaluation of bivalirudin as an alternative to heparin in pediatric ecls. Crit Care Med. 2018;46:99.

Article  Google Scholar 

Havlin K, Feygin Y, Calhoun A, Sparks J, Tzanetos D. Pediatric ECMO antcoagulaton: Heparin vs. Bivalirudin; A single center experience. ASAIO J. 2020;66:39.

Article  Google Scholar 

Kamerkar A, Kyle K, Nelson L. A Comparison of Bivalirudin and Heparin for Children on ECMO. ASAIO J. 2020;66(SUPPL 3):44.

Google Scholar 

Khouli C, Converse M, Wang IW. Incidence of venous thromboembolism in ECMO patients receiving bivalirudin compared with heparin. Crit Care Med. 2016;44(12):115.

Article  Google Scholar 

McMichael A, Zia A, Weller J, Hill D, Darling J, Raman L. Prospective randomized pilot study comparing bivalirudin versus heparin in neonatal and pediatric extracorporeal membrane oxygenation. Perfusion (germany). 2019;34(1):246-.

Google Scholar 

Menk M, Briem P, Weiss B, Gassner M, Schwaiberger D, Goldmann A, Pille C, Weber-Carstens S. Efficacy and safety of argatroban in patients with acute respiratory distress syndrome and extracorporeal lung support. Ann Intensive Care. 2017;7(1):82. https://doi.org/10.1186/s13613-017-0302-5.

Meyer K, Davidson K, Thompson M, Daniel J. The use of bivalirudin in comparison to heparin for anticoagulation in neonatal ECMO patients. ASAIO J. 2021;67(SUPPL 1):25.

Google Scholar 

Muller Moran H, Eikelboom R, Ariano R, Manji R. Should direct thrombin inhibitors be the anticoagulant of choice for patients on extracorporeal membrane oxygenation? Can J Cardiol. 2020;36(10):S105–6.

Article  Google Scholar 

Patel K, Saraf P, Shiu D, Patel C, Ali N, Lee J, Junaid N, Patel P, Anandarangam T, Seethamraju H. Safety profile of argatroban vs heparin for anticoagulation in patients requiring Extra Corporeal Membrane Oxygenation (ECMO) therapy. Chest. 2015;148(4).

Phan F, Kojiro K, Hill J, Brookshire R, Ogston T, Grover V, Wanek S, Deng J, Turner B. Safety and efficacy of bivalirudin for systemic anticoagulation in venovenous extracorporeal membrane oxygenation. ASAIO Journal. 2019;65:50-.

Article  Google Scholar 

Rivosecchi RM, Grayson M, Sappington PL. Comparison of bivalirudin versus heparin-based anticoagulation for extracorporeal membrane oxygenation. ASAIO J. 2018;64:22.

Google Scholar 

Schill MR, Douds MT, Burns EL, Said AS, Abarbanell AM. Is bivalirudin comparable to heparin anticoagulation for pediatric extracorporeal life support? Results from a high-volume center. Artif Organs. 2020;44(4):E184.

Google Scholar 

Seelhammer T, Friedrich T, Aganga D, Bohman K. Reduced mortality with bivalirudin-based versus conventional heparinbased anticoagulation for adult and pediatric patients supported on extracorporeal membrane oxygenation. ASAIO J. 2019;65:89.

Article  Google Scholar 

Varnado S, Parkin S, Oldham C, Henry K, Gutteridge D. Bivalirudin as an Alternative to Heparin in COVID-19 Patients Managed on VV ECMO. ASAIO J. 2020;66(SUPPL 3):23.

Google Scholar 

Welp H, Sidermann J, Martens S, Gottschalk A, Scherer M. Anticoagulation with argatroban in patients undergoing extracorporal life support system therapy. Thoracic and Cardiovascular Surgeon 2018;66.

Giuliano K, Bigelow BF, Etchill EW, Velez AK, Ong CS, Choi CW, Bush E, Cho SM, Whitman GJR. Extracorporeal Membrane Oxygenation Complications in Heparin- and Bivalirudin-Treated Patients. Crit Care Explor. 2021;3(7):e0485.

PubMed  PubMed Central  Article  Google Scholar 

Ryerson LM, Balutis KR, Granoski DA, Nelson LR, Massicotte MP, Lequier LL, Bauman ME. Prospective Exploratory Experience With Bivalirudin Anticoagulation in Pediatric Extracorporeal Membrane Oxygenation. Pediatr Crit Care Med. 2020;21(11):975–85.

PubMed  Article  Google Scholar 

Sattler LA, Boster JM, Ivins-O’Keefe KM, Sobieszczyk MJ, Reel BA, Mason PE, Walter RJ, Sams VG. Argatroban for Anticoagulation in Patients Requiring Venovenous Extracorporeal Membrane Oxygenation in Coronavirus Disease 2019. Crit Care Explor. 2021;3(9):e0530.

PubMed  PubMed Central  Article  Google Scholar 

Han SJ, Han W, Song HJ, Kim CS, Jeong SM, Kang MW. Validation of Nafamostat Mesilate as an Anticoagulant in Extracorporeal Membrane Oxygenation: A Large-Animal Experiment. Korean J Thorac Cardiovasc Surg. 2018;51(2):114–21.

PubMed  PubMed Central  Article  Google Scholar 

Han SJ, Kim HS, Kim KI, Whang SM, Hong KS, Lee WK, Lee SH. Use of nafamostat mesilate as an anticoagulant during extracorporeal membrane oxygenation. J Korean Med Sci. 2011;26(7):945–50.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Han W, Bok JS, Cho HJ, Yu JH, Na MH, Kang S, Kang MW. Single-center experience of extracorporeal membrane oxygenation mainly anticoagulated with nafamostat mesilate. J Thorac Dis. 2019;11(7):2861–7.

PubMed  PubMed Central  Article  Google Scholar 

Han W, San Bok J, Cho HJ, Yu JH, Na MH, Kang S, Kang MW. Single-center experience of extracorporeal membrane oxygenation mainly anticoagulated with nafamostat mesilate. J Thorac Dis. 2019;11(7):2861–7.

PubMed  PubMed Central  Article  Google Scholar 

Lim JY, Kim JB, Choo SJ, Chung CH, Lee JW, Jung SH. Anticoagulation During Extracorporeal Membrane Oxygenation; Nafamostat Mesilate Versus Heparin. Ann Thorac Surg. 2016;102(2):534–9.

PubMed  Article  Google Scholar 

Berei TJ, Lillyblad MP, Wilson KJ, Garberich RF, Hryniewicz KM. Evaluation of Systemic Heparin Versus Bivalirudin in Adult Patients Supported by Extracorporeal Membrane Oxygenation. Asaio j. 2018;64(5):623–9.

CAS  PubMed 

留言 (0)

沒有登入
gif